Support in the form of educa- tional grants was also provided by Bristol-Myers Squibb; P zer, Inc; Canyon Pharmaceuticals; and sano -aventis US. Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S. Correspondence to: Gregory Y. H. Lip, MD, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, B18 7QH, England; e-mail: g.y.h.lip@bham.ac.uk 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/ site/misc/reprints.xhtml). Summary of Recommendations Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommenda- tions sections to indicate recommendations that are newly added or have been changed since the publica- tion of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded. 2.1.8. For patients with AF, including those with paroxysmal AF, who are at low risk of stroke (eg, CHADS2 [congestive heart failure, hyper- tension, age 75 years, diabetes mellitus, prior stroke or transient ischemic attack] score 0), we suggest no therapy rather than antithrom- botic therapy (Grade 2B). For patients who do choose antithrombotic therapy, we suggest aspi- rin (75 mg to 325 mg once daily) rather than www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e533S For patients with AF at low to intermediate risk of stroke (eg, CHADS2 score of 0 or 1) during the rst 12 months after placement of an intracoronary stent (bare metal or drug eluting), we suggest dual antiplatelet ther- apy rather than triple therapy (Grade 2C). 